Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Nvidia Develops New Location-Verification Technology for AI Chips 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Rite Aid, an American drug store chain, has been given the “go ahead” signal by the court for selling its Elixir Solutions pharmacy and services company. It has received the needed approval amid its ongoing restructuring after filing for bankruptcy in the last quarter of 2023.
Rite Aid Corp. is now set to sell its Elixir pharmacy chain to MedImpact Healthcare Systems, Inc. It was reported that the companies agreed to the sale price of $575 million.
Putting Elixir on the Market
As per Reuters, during its bankruptcy, Rite Aid placed its Elixir business in the market and continued to offer it to more than 30 potential buyers. However, it did not find any bidder that offered a higher price than MedImpact.
This information was shared by the company’s lawyer, Ross Fiedler, on Tuesday, Jan. 9, during a bankruptcy court hearing held in Trenton, New Jersey.
The lawyer shared that selling Elixir is a vital aspect of the company’s effort to raise funds and re-direct its focus on its retail pharmacy operations amid the bankruptcy. Fiedler told U.S. Bankruptcy Judge Michael Kaplan that Rite Aid’s sale of Elixir is expected to close within the first quarter of this year.
Positive Impact of Elixir’s Sale
The transaction is still subject to some customary closing conditions like the other sale deals. Until its completion, Elixir will still be part of Rite Aid and continue operating under the company as usual.
In any case, Judge Kaplan approved the sale during the recent hearing. With this decision, Rite Aid is now making considerable progress in its restructuring to achieve long-term success in the market. Moreover, the sale to MedImpact will maximize the value while putting Elixir in a better position to support its clients and customers.
“We are pleased to receive this key approval toward the sale of our Elixir business to MedImpact,” Rite Aid’s chief executive officer and restructuring officer, Jeffrey S. Stein, said in a press release. “We are confident the transaction with MedImpact maximizes the value of the business and best positions Elixir to support clients, members and customers long into the future. We are grateful to the Elixir team for their hard work and dedication throughout this process.”
The CEO continued to say, “We are continuing to make progress with our court-supervised process and are moving forward with our Rite Aid 2.0 Plan. We remain focused on providing leading healthcare products and services to the customers that we serve every day.”
Photo by: Rite Aid Press Release
